Medicis, Teva Resolve Solodyn Patent Suit

Law360, New York (February 28, 2011, 8:20 PM EST) -- Medicis Pharmaceutical Corp. on Monday resolved its claims in a Maryland federal court that Teva Pharmaceutical USA Inc. infringed two patents through a generic version of acne drug Solodyn.

Teva and its subsidiary Barr Laboratories Inc. are permanently enjoined from making generic Solodyn except as laid out in license agreements with Medicis, according to a consent judgment signed by Judge Frederick Motz of the U.S. District Court for the District of Maryland.

The parties said they reached a separate agreement settling infringement claims, but court documents...
To view the full article, register now.